BioSpace News Archive

Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation.

Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function.

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.

Hexagon Bio is a data-driven biopharma company developing targeted small molecule therapeutics. Our proprietary platform combines data science, genomics, synthetic biology, chemistry and automation to discover potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Cell Microsystems’ transformative platforms for cell engineering, culture, and analysis empower laboratories worldwide to unlock the full potential of their cells, making what was once impossible possible.

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.

Scioderm, Inc. was acquired by Amicus Therapeutics, Inc. in September of 2015. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare genetic diseases.